- Published at
- by manilatimes.net
mixed
mixed
News for Biogen Inc. (BIIB)
- Published at
- by gurufocus.com
positivepositiveLeqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveBiogen (BIIB) Achieves EU Approval for Leqembi in Alzheimer's Treatment | BIIB Stock News
The European Commission has officially approved the marketing of Leqembi, an amyloid-beta monoclonal antibody developed by Biogen (BIIB), for use across the Eur- Published at
- by gurufocus.com
positivepositiveOrganon (OGN) Bolsters U.S. Immunology Portfolio with TOFIDENCE Acquisition
Organon (OGN) strategically expands its portfolio by acquiring U.S. rights for the biosimilar TOFIDENCE from Biogen (BIIB). Analysts provide a favorable- Published at
- by gurufocus.com
mixedmixedSAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm
PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. ( SAGE) (”Sage”) on behalf of- Published at
- by zacks.com
neutralneutralBiogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.- Published at
- by zerohedge.com
mixedmixed- Published at
- by seekingalpha.com
positivepositiveBiogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen's Alzheimer’s therapy BIIB080 gains FDA Fast Track status, expediting its development. Read more here.- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
mixedmixedBiogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) —- Published at
- by seekingalpha.com
neutralneutralOrganon buys rights to Biogen’s Actemra biosimilar (OGN:NYSE)
Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting Roche's (RHHBY) Actemra. Read more here.- Published at
- by manilatimes.net
mixedmixed- Published at
- by livemint.com
negativenegativeEli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing
(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh t...- Published at
- by gurufocus.com
positivepositiveBiogen Inc (BIIB) Announces New Global Headquarters at Kendall Common
Biogen Inc (BIIB) has announced plans to establish its new global headquarters at Kendall Common in Cambridge, Massachusetts, as part of a multi-year real estat- Published at
- by manilatimes.net
positivepositive- Published at
- by economictimes.indiatimes.com
mixedmixedThe next big market boom? Mizuho analysts say baby boomers’ spending, not AI, will be a silver tsunami, to unlock a $1 trillion opportunity
Mizuho Financial Group analysts reveal that the spending power of America's aging population, particularly those aged 75 and above, will significantly impact the market, unlocking a $1 trillion opportunity, termed- Published at
- by businessinsider.com
mixedmixedThere's a $1 trillion opportunity brewing in the stock market — and it's got nothing to do with AI
Americans over the age of 75 are expected to grow their spending by more than $2 trillion in the next 10 years, according to Mizuho.- Published at
- by gurufocus.com
positivepositiveMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Can- Published at
- by seekingalpha.com
positivepositiveBiogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ETCompany ParticipantsPriya Singhal - Head of...